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Abstract
In mice, the transcription factor, PLZF, controls the development of effector functions in invariant NKT cells and a subset of
NKT cell-like, cd T cells. Here, we show that in human lymphocytes, in addition to invariant NKT cells, PLZF was also
expressed in a large percentage of CD8+ and CD4+ T cells. Furthermore, PLZF was also found to be expressed in all cd T cells
and in all NK cells. Importantly, we show that in a donor lacking functional PLZF, all of these various lymphocyte populations
were altered. Therefore, in contrast to mice, PLZF appears to control the development and/or function of a wide variety of
human lymphocytes that represent more than 10% of the total PBMCs. Interestingly, the PLZF-expressing CD8+ T cell
population was found to be expanded in the peripheral blood of patients with metastatic melanoma but was greatly
diminished in patients with autoimmune disease.
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Introduction
The promyelocytic leukemia zinc finger (PLZF, ZBTB16)
transcriptional regulator is a member of the BTB/POZ-ZF (Broad
complex, tramtrack, bric-a `-brac or poxvirus and zinc finger-zinc
finger; BTB-ZF) family of proteins that have a wide variety of
biological activities [1]. Over the last few years, it has become
apparent that BTB-ZF proteins are critical regulators of immune
system development and function. For example, Bcl6 has been
shown to be necessary for both the B cell germinal center reaction
[2,3] as well as for the development of follicular helper T cells
[4,5]. ThPok has been shown to be necessary and sufficient for
CD4 T cell development [6] and the B cell versus T cell
commitment step is controlled by LRF (leukemia/lymphoma
related factor) [7]. Mazr influences CD8 T cell development, in
part by regulating the expression of ThPok [8].
PLZF was first identified due to a t(11;17)(q23;q21) transloca-
tion that fused PLZF with RARa(retinoic acid receptor alpha) in
some patients with acute promyelocytic leukemia (APL) [9]. The
fusion protein that results from this translocation was subsequently
shown to be an important determining factor in the development
APL and its response to therapy with retinoic acid [10]. The
transcription factor has since been implicated in a wide variety of
developmental processes, including axial skeletal patterning [11],
CNS development [12], male spermatogenesis [13,14], and
immune function [15].
Recently it was shown that PLZF is highly expressed in mouse
and human invariant natural killer T (iNKT) cells [16,17]. NKT
cells represent a subset of CD3
+ lymphocytes that serve as a bridge
between the innate and adaptive immune systems. Invariant NKT
cells represent a subset that expresses a CD1d-restricted Va24Ja18
TCR in humans [18,19]. Both variant and invariant subsets are
capable of rapid and copious secretion of a wide variety of Th1
and Th2 cytokines upon initial stimulation, although evidence
suggests that the specific roles of each subset may differ [20]. The
invariant TCR expressed by iNKT cells recognizes lipid antigens
presented in the context of the MHC class I-like molecule CD1d.
Invariant NKT cells, which have been extensively studied in mice,
are, comparatively, quite rare in humans. For example, in mice
30–40% of T cells in the liver are iNKT cells; in humans only
,1% of hepatic T cells are iNKT cells [21,22,23]. Only 0.008–
1.1% of human peripheral blood T cells and only 0.001–0.01% of
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24441human thymocytes have been reported to be iNKT cells
[24,25,26].
Our lab, and others, have shown that in mice, PLZF controls
the development of essentially all of the innate-like features of
NKT cells [16,17]. For example, PLZF-deficient NKT cells do not
acquire the typical ‘‘activated’’ phenotype characterized by high
expression of CD44 and CD69 [16,17]. PLZF deficient NKT cells
also do not constitutively express granzyme B or the mRNA
transcript for IL-4 [16] and fail to acquire the capacity to secrete
multiple cytokines upon primary stimulation [16,17]. Further-
more, the frequency of NKT cells is substantially reduced in
PLZF-deficient mice and the cells accumulate in the lymph nodes
and spleen rather than in the thymus and liver. Overall, the
phenotype of PLZF-deficient NKT cells is highly reminiscent of
naı ¨ve, conventional CD4 T cells [16]. In contrast, ectopic
expression of PLZF in conventional T cells results in the
acquisition of innate T cell-like characteristics such as an activated
phenotype, the rapid secretion of Th1 and Th2 cytokines in
response to an initial stimulus and homing to non-lymphoid tissues
[17,27,28].
Recent studies have shown that PLZF expression is not strictly
limited to invariant NKT cells in mice, but can also be found in a
specific subset of cd T cells that express a Vc1.1Vd6.3 TCR
[29,30,31]. This subset of ‘‘NKT’’ cd T cells functionally resemble
invariant NKT cells in that they co-secrete both IFN-c and IL-4
upon primary activation. Importantly, PLZF has been shown to be
required for the innate T cell-like characteristics of NKT cd T cells
[29]. These studies, together with the findings in NKT cells,
highlight an essential and non-redundant role for PLZF in the
development of innate T cell effector functions.
In addition to directly controlling the function of the cells it is
expressed within, PLZF impacts immune function in trans. Of
great interest, studies show that the IL-4 produced by these PLZF-
expressing cells profoundly alters the CD8 T cell compartment
[32,33]. In mice with an expanded PLZF-expressing T cell
compartment, CD8 T cells were found to take on an innate-like
phenotype, represented by increased expression of CD44, Eomes
and an enhanced capacity to secrete IFN-c. Such mice also harbor
increased numbers of germinal center B cells and high serum levels
of IgE, in concordance with their heightened Th2 responses [31].
These data show that innate-like T cells, such as NKT cells, have a
broad impact on the immune response.
The role of NKT cells in disease is complex and appears to be
dependent on both the NKT cell subtype and the microenviron-
mental context. In mice, NKT cells have been shown to be
important in the suppression of solid tumors as a consequence of
interactions with dendritic cells and other lymphocytes
[34,35,36,37,38,39,40]. In contrast, the immunomodulatory
activity of NKT cells can also influence the immune response
against autoantigens. For example, autoimmunity in the Type 1
diabetes-susceptible NOD mouse appears to be exacerbated by a
deficiency of invariant NKT cells since it is alleviated by NKT
activation [41]. In humans with autoimmune diseases, including
systemic lupus erythematosus (SLE) [42], diabetes mellitus, and
rheumatoid arthritis, decreases in circulating NKTs have, in some
studies, been shown to correlate with the frequency of disease [43].
Spurred by recent reports of a broader expression pattern of,
and functional relevance for, PLZF in mouse lymphocytes, we
examined the full breadth of PLZF expression in human T cells.
Furthermore, analysis of the only known person to harbor a
biallelic loss of PLZF enabled us, for the first time, to examine the
role of this transcription factor in the development of human T
cells. We found that in addition to iNKT cells, nearly all cd T cells
and natural killer (NK cells) expressed PLZF. Furthermore, more
than 5% of CD8
+ T cells and ,2% of CD4
+ T cells were found to
express the transcription factor. Therefore, in total, more than
10% of human PBLs express PLZF. Finally, to study the
importance of PLZF for the development of these various cell
types, we obtained peripheral blood samples from the only person
known to harbor a biallelic loss of functional PLZF [44]. Overall,
our data suggest that differences in PLZF expression represent a
significant divergence between the mouse and human immune
system.
Materials and Methods
Blood Draw
Blood draw protocols and ethics were reviewed and approved
by the Internal Review Board’s (IRB) at Memorial Sloan-
Kettering Cancer Center (New York, NY), the Hospital for
Special Surgery (New York, NY), the Winthrop-University
Hospital (Mineola, NY) and Universitaetsklinikum Essen (Essen,
Germany). Written informed consent forms were obtained from all
donors.
Flow Cytometry
Anti-CD3-Pacific Blue-CD4-PerCPCy5.5, -CD8-AlexaFluor700,
CD56-PECy7, -CD161-APC, -cdTCR-PE, -Va24-Ja18-PE, and –
CD4-AlexaFluor488, were obtained from BD, eBioscience or
BioLegend. Mags.21F7 (anti-PLZF) was described [16]. Dead cells
were excluded by DAPI when possible and doublets were excluded.
Cell sorts were done by MSKCC’s Flow Cytometry Core Facility.
Post-sort analysis confirmed cell purity .95%.
Cytokine Expression
T cells were plated in X-vivo media with PMA (100 ng/ml) and
ionomycin (500 ng/ml) or beads coated with anti-CD3/CD28
(Miltenyi Biotec). Brefeldin A was added for the last five hours of a
6 hour culture. Cells were stained for surface markers, fixed, made
permeable and stained with anti-IFNc AlexaFluor 488 (BD). NK
cells were activated with beads coated with anti-NKp46 and anti-
CD2 (Miltenyi Biotec). Cytokines were analyzed with cytokine
bead arrays (BD).
Patient Samples
Patients with an established diagnosis of systemic lupus
erythematosus (SLE, n=6), primary Sjo ¨gren’s syndrome (n=3),
or metastatic melanoma (n=10) and healthy controls (n=8) were
consented in accordance with local institutional review board
guidelines. Lymphocytes were isolated from patients with stage III-
IV melanoma by leukapheresis. Lymphocytes from fresh periph-
eral blood for other samples were isolated by Ficoll extraction.
Real Time PCR
Sorted cells were suspended in 1 ml Trizol and frozen at -80
degrees. RNA was isolated using Qiagen’s RNeasy mini kit.
Following reverse transcription, the abundance of PLZF cDNA
was quantified by real-time PCR using the MasterMix (2X)
HotStart-IT Syber kit (USB). Expression levels were normalized
against the housekeeping gene GAPDH, according to the formula:
relative PLZF induction =2
CT(GAPDH) – CT(PLZF).
Statistical Methods
Statistical analysis was done either with a two-tailed, unpaired
Student’s t-test or the Mann-Whitney U-test, which is a more
robust for small sample sizes.
PLZF and the Human Immune System
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e24441Results
PLZF expression in human T cells
PLZF is expressed both in mouse and human invariant NKT
cells [16]. Recent studies in mice, however, show that PLZF
expression is not limited to this cell type [29,30,31]. Therefore, we
more carefully examined the expression of PLZF in PBLs from
healthy volunteers by FACS. Similar to mice, PLZF was not
detected in ‘‘conventional’’ T cells (Fig. 1A). The cd TCR and
iNKT cell-negative, CD3
+ T-cell compartment can be demarcat-
ed by the expression of CD161 and CD56. These cells are found
at fairly high frequencies, with CD56
+ T cells on average at 1.7%
(+/-2.5%) and CD161
+ T cells often found at more than 10% of
the total T cells (Fig. 1B). CD56
+ T cells, which are often are
considered to be non-invariant NKT cells, did not express PLZF
(Fig. 1C). Similarly, CD161
lo cells (white box, Fig. 1B) also did
not express PLZF. Of particular interest, however, was a distinct
population of T cells (3.4% +/22.5%) marked by high levels of
CD161 (Fig. 1B) that clearly expressed PLZF (Fig. 1C).
The majority of the PLZF-expressing CD161
hi T cells were
found to be CD8
+ (Fig. 1D). Furthermore, the CD161
hiCD8
+ T
cells (Fig. 1E), expressed higher levels of PLZF as compared to the
CD161
hiCD4
+ T cells (Fig. 1F). PLZF expression was lower than
in iNKT cells (Fig. 1F). PLZF expression levels were consistent
among cells from eight healthy donors (Fig. 1G). Expression levels
were also confirmed by rtPCR of sorted cell populations (Fig. 1H).
The CD161
hiCD8
+ population represented, on average, ,6% of
the total CD8
+ T cells (Figs. 1B, 1E). PLZF is not expressed in
any identified CD8
+ T cell population in mice [16]and
unpublished data). Therefore, PLZF expression defines an
abundant T cell subgroup in humans that does not exist in mouse
peripheral blood.
To determine if the CD161
hi subset arose from the CD161
2
population as a result of activation, CD8
+ and CD4
+ T cells that
were CD161
2 (Fig. 1I, black lines) or CD161
hi (Fig. 1I, red lines)
were sorted and cultured with beads coated with antibodies against
CD3 and CD28. After three days, low levels of CD161 were
induced on the CD161
2 T cells (Fig. 1J, black lines). CD161
hi
CD8
+ T cells were found to retain high levels of CD161 expression
post-activation (Fig. 1J, red lines). The CD161
hi CD4
+ T cells,
however, downregulated CD161 post-activation (Fig. 1J, red
lines). Therefore, the CD161hi phenotype is specific to the PLZF-
expressing CD8
+ T cells and expression of high levels of CD161
cannot be induced by activation. Furthermore, PLZF was not
induced in non-PLZF expressing T cells by activation (data not
shown).
Next we activated PBMCs with either PMA/ionomycin or anti-
CD3 and anti-CD28, followed by FACS analysis for IFN- c
production. Surprisingly, unlike PLZF-expressing cells in mice
[16,29], few PLZF-expressing CD161
hiCD8
+ T cells produced
IFN-c (Fig. 1K). As expected, many PLZF-negative CD161
2CD8
+
T cells produced IFN-c upon stimulation (Fig. 1K).
The frequency of PLZF-expressing CD161
hiCD8
+ T cells is
altered in patients with autoimmunity or advanced
melanoma
To begin to study the role of PLZF-expressing CD161
hiCD8
+ T
cells in the human immune response, we obtained peripheral
blood samples from patients with systemic autoimmune diseases or
malignancy. Patient samples were collected based only on
availability; no selection criteria were utilized and treatment status
was unknown. Monocyte-depleted PBMCs were stained with
antibodies against CD3, CD4, CD8, CD161, CD56 and cd TCR,
then analyzed by flow cytometry. Two representative samples
acquired from patients diagnosed with systemic lupus erythema-
tosus (SLE) is shown in Fig. 2A. CD161
hi T cells appeared to be
reduced, but not to a level that reached statistical significance,
when the SLE samples were compared to healthy donors (Fig. 2A).
The apparent reduced frequency of CD56
+ T cells also did not
reach statistical significance (data not shown). There was, however,
a clear reduction in the percentage of CD8
+ cells within the
CD161
hi population in patients with SLE (Fig. 2B). Similarly, the
frequency of CD161
hi cells within the CD3
+CD8
+ T cell
population was significantly reduced in the SLE samples, as
compared to healthy controls (Fig. 2C). Again, the apparent
reduction of CD3
+CD8
+CD56
+ was not statistically significant
(data not shown). A similar trend was seen in a limited survey of
patients with primary Sjogren’s syndrome (data not shown).
Finally, the residual CD161
hiCD8
+ T cells in the SLE patients
expressed little or no PLZF (Fig. 2D).
Next, we evaluated the frequency of CD161
+ T-cells in blood
samples from ten patients with advanced melanoma. In contrast to
our findings in SLE and Sjogren’s patients, we observed a
substantial increase in the frequency of CD161
hi T cells in the
melanoma cohort as compared to healthy controls (Fig. 3A).
Different than the patients with autoimmunity, there was no
change in the frequency of the CD8 to CD4 ratio within the
CD161
hi T cells (Fig. 3B). Among the CD8
+ T cells, however,
there was a substantial increase in the percentage of CD161
hi T
cells (Fig. 3C). Also different than the SLE samples, the
CD161
hiCD8
+ T cells in the patient samples were found to
express PLZF at levels similar to healthy donors (Fig. 3D). These
data, along with published studies [45], show that the PLZF-
expressing PBL T cell population changes in patients with disease.
T cell subset deficiencies as a consequence of a biallelic
loss of functional PLZF
Recently, the first and, to our knowledge, only person with a
biallelic loss of functional PLZF was identified [44]. The maternal
allele of PLZF was found to have a missense mutation that resulted
in a methionine to valine substitution within a zinc finger domain.
This mutation is paired with the paternal chromosome harboring
a de novo deletion of ,8 Mbp, resulting in the loss of the gene
encoding PLZF. Peripheral blood from this person was obtained
and analyzed by FACS. In the absence of PLZF, the total
percentage of CD3
+ T cells among PBLs and the percentage of
CD4
+ and CD8
+ T cells were similar to healthy controls (Fig. 4A).
The frequency of the CD56
+ and the CD161
hi T cell populations,
however, were reduced as compared to the mean frequency found
in healthy controls (Fig. 4B,C) and the few CD56
+ and CD161
hi
cells found did not express PLZF (Fig. 4D). The few CD161
hi cells
observed in this donor were strongly skewed towards CD4 rather
than CD8 expression, which contrasted with the pattern observed
in healthy controls (Fig. 4E,F). Additionally, there was a decrease
in frequency of CD161
hi DN T cells, as compared to controls
(Fig. 4E,F).
Human iNKT cells require PLZF for normal development
In mice, iNKT cells develop in the absence of PLZF, but they do
not acquire innate T cell characteristics [16,17]. For example, in
mice, PLZF-deficient iNKT cells accumulate in the lymph nodes
rather than in the liver, do not express high levels of CD44 and
CD69 and, also, fail to make cytokines upon primary activation.
PLZF-deficient mouse iNKT cells are highly skewed towards CD4
and express low levels of NK1.1 [16]. iNKT cells are also present in
the peripheral blood of PLZF-deficient mice, but at a reduced
frequency as compared to wild type mice (data not shown). The
frequency of human iNKT cells in the PLZF-deficient donor was
PLZF and the Human Immune System
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24441Figure 1. Expression of PLZF in peripheral T cell subsets. (A) Intranuclear FACS analysis of PLZF expression in total CD3
+ T cells; (B) CD161 and
CD56 expression on CD3
+, NKT cell
2, cd TCR
2 lymphocytes; (C) PLZF expression in the indicated cell populations. Expression is compared to that of
PLZF negative CD3
+CD161
2CD56
2 conventional T cells (black line). (D) CD4 and CD8 expression on electronically gated CD3
+CD161
hi T cells. (E)
CD161 expression on electronically gated CD3
+CD8
+ T cells. (F) PLZF expression in the indicated cell populations. (G) Mean fluorescence intensity
(MFI) of PLZF expression in indicated cells (N=8). P values are indicated (n.s. = not significant); (H) cDNA made from RNA collected from the
indicated populations was analyzed by real-time quantitative rtPCR. Units are relative to the expression of GAPDH. Data are the average of two
independent experiments with an N=4. (I) Healthy donor lymphocytes were sorted into four T cell subsets: CD161
2CD4
+, CD161
2CD8
+,
CD161
hiCD4
+ and CD161
hiCD8
+. Representative data for CD161 expression on the four populations analyzed immediately post-sort is shown (black
line = CD161
2 cells; red line = CD161
hi cells). (J) CD161 levels of the indicated sorted cells, analyzed three days after activation with anti-CD3/CD28
coated beads, is shown (black line = CD161
2 cells; red line = CD161
hi cells). (K) IFN- c expression by peripheral blood T cells 6 hours after activation
with PMA/Ionomycin or anti-CD3/C28 coated beads. Numbers indicate percentage of cells within the indicated gate. Data in A–G are representative
of eight donors, each analyzed at least two times. Data in I and J are representative of two individuals done in two independent experiments. Data
shown in K are from two different individuals and were two independent experiments.
doi:10.1371/journal.pone.0024441.g001
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healthy controls (Fig. 5A). However, the phenotype of the PLZF-
deficient iNKT cells clearly resembled that of iNKT cells from
PLZF-deficient mice. In particular, PLZF-deficient human iNKT
cellswere stronglyskewedtowards expressingCD4attheexpenseof
the DN population (Fig. 5B). Furthermore, the PLZF deficient
iNKT cells were largely CD161 (NK1.1) low (Fig. 5C). These data
suggest that, similar to the findings in mice, PLZF impacts the
development of iNKT cells in humans.
Human cd T cells express PLZF
The reduction in the frequency of CD161
hi DN T cells in the
absence of PLZF (Fig. 4E,F) prompted us to more carefully
examine this population of T cells. A large percentage of the
CD161
hi DN T cells proved to be cd T cells (data not shown). We,
and others, recently reported the existence of a minor subset of
NKT cell-like cd T cells in mice that express high levels of PLZF
[30,31]. Unlike the subset-restricted pattern of PLZF expression in
mouse cd T cells, all human peripheral blood cd T cells were
Figure 2. Patients with systemic lupus erythematosus show decreased circulating have altered frequencies of PLZF-expressing T
cells. (A) The frequency of CD161
hi lymphocytes within the CD3
+ cd TCR
2 population. (B) The CD4/CD8 profile of the CD161
hi T cells as identified in
(A). (C) The frequency of CD161
hi T cells within the CD3
+CD8
+ cd TCR
2 lymphocyte gate. (D) The remaining CD161
hiCD8
+ T cells in SLE patients
express low levels of PLZF. PBMC’s were collected from six patients with SLE and stained as previously described. A representative control and two
patient samples are shown for each analysis. Data from the control and patient groups are summarized in scatter plots. P values are shown in figures
(n.s. = not significant).
doi:10.1371/journal.pone.0024441.g002
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confirmed by comparing cd T cells from healthy donors to cd T
cells from the PLZF-deficient donor (Fig. 6A). cd T cells were
found to develop in the absence of PLZF and were present at a
frequency similar to that published by others (,4%) [46] and to a
larger panel of samples we analyzed (Fig. 6B and data not
shown). The data suggests that the frequency of CD161
hi cd T
cells was reduced in the absence of PLZF, while the frequency of
CD8
+ cd T cells was increased (Fig. 6B), however, cd T cell
phenotypes were found to be highly variable among healthy
donors.
Human NK cells express PLZF
Less than 5% of mouse NK cells constitutively express PLZF
[16] and PLZF is not induced in mouse NK cells by activation
(data not shown). Furthermore, mouse NK cells develop and
appear to function normally in PLZF-deficient mice ([16] and data
not shown). Therefore it was very surprising to find that nearly all
Figure 3. Patients with advanced melanoma have expanded circulating CD8
+ CD161
hi T cell populations. (A) The frequency of CD161
hi
lymphocytes within the CD3
+ cd TCR
2 population. (B) The CD4/CD8 profile of the CD161
hi T cells as identified in (A). (C) The frequency of CD161
hi T
cells within the CD3
+CD8
+ cd TCR
2 lymphocyte gate. (D) CD161
hiCD8
+ T cells from patients with advanced melanoma retain PLZF expression, as
compared to conventional CD8 T cells. PBMC’s from ten patients with metastatic melanoma were isolated via leukapheresis. The cells were stained
and analyzed by FACS as described above. A representative control and two patient samples are shown for each analysis. Data from the control and
patient groups are summarized in scatter plots. P values are shown in figures (n.s. = not significant).
doi:10.1371/journal.pone.0024441.g003
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24441Figure 4. PBMCs from a person with a biallelic loss of functional PLZF were analyzed by FACS. (A) The frequency of CD3
+ T cells and the
CD4/CD8 of the CD3
+ T cells was not altered as compared to healthy donor samples. Results shown are representative of three experiments. (B) Dot
plot shows the frequency of CD161
hi and CD56
+ expression on CD3
+ T cell from the PLZF-deficient donor. cd T cells were excluded from the analysis.
(C) Scatter plot shows the frequency of the CD161
hi and CD56
+ T cell subsets from the PLZF-deficient donor in comparison to healthy controls
(Cont.= healthy control; Def. = PLZF-deficient). (D) Histogram shows PLZF expression in CD3
+ CD161
hi and CD56
+ T cells from the PLZF deficient
donor in comparison to the donor’s conventional T cells (CD56
2CD161
2). (E) CD8 versus CD4 expression on NKT cell
2, cd T cell
2, CD161
hi T cells from
the PLZF-deficient donor. (F) Scatter plot shows CD8, CD4 and DN distribution of CD161
hi T cells from the PLZF-deficient donor as compared to
healthy controls. Numbers within FACS plot represent the percentage of events in the indicated gate. Results were consistent in three samples that
were obtained from the PLZF deficient donor.
doi:10.1371/journal.pone.0024441.g004
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24441human NK cells expressed the transcription factor. The expression
of PLZF was made clear by comparing samples from healthy
donors to the PLZF-deficient donor (Fig. 7A)
PLZF-deficient NK cells were found to express lower levels of
CD56, CD16 and CD161 (Fig. 7B). To assess the functional
relevance of PLZF in human NK cells, NK cells from healthy
controls and the PLZF-deficient donor were activated with beads
coated with antibodies against CD335 (NKp46) and CD2.
Supernatants were collected after three days for cytokine analysis.
There was a clear increase in the amount of secreted IFN- c, TNF
and Granzyme B in the PLZF-deficient sample as compared to the
control samples (Fig. 7C). GM-CSF was also found to be
increased, but to a lesser degree. Therefore, PLZF expression
appears to subdue cytokine secretion by human NK cells.
Discussion
We show that in people, CD8
+ and CD4
+ CD161
hi T cells, all
cd T cells, NKT cells and all NK cells express PLZF. Collectively,
these populations represent more than 10% of the total human
peripheral blood lymphocytes. In contrast, PLZF expression in
mice is limited to NKT cells and a minor subset of cd T cells,
which combined, account for ,1% of the total lymphocytes.
Furthermore, few, if any, mouse NK cells express PLZF.
Therefore, PLZF arguably plays a far more significant role in
the human immune system than in that of the mouse.
Figure 5. Invariant NKT cell development is altered in the
absence of PLZF. (A) Invariant NKT cells from the PLZF-deficient and a
healthy control donor identified with antibodies against the Va24Ja18
iTCR antibody (6B11) and CD3. The scatter plot shows the frequency of
iNKT cells in the PLZF-deficient as compared to healthy donors. The
healthy control sample shown in the dot plot was acquired in the same
experiment as the PLZF deficient sample. Therefore, this sample is
shown although the frequency of iNKT cells is higher than the median
for all samples. (B) Dot plots show the expression of CD4 and CD8 on
iNKT cells identified in (A). The scatter plots show the frequency of CD4
+
and CD4
2CD8
2 double negative (DN) iNKT cells from the PLZF-deficient
donor as compared to healthy controls. (C) Histogram shows a
comparison of CD161 expression on iNKT cells from the PLZF-deficient
donor to healthy controls. iNKT cells were identified as shown in (A).
The scatter plot compares the frequency of CD161
hi iNKT cells from the
PLZF-deficient donor as compared to healthy controls. High expression
of CD161 was defined by the black bar shown in the histogram. Cont.=
health control; Neg. = PLZF deficient.
doi:10.1371/journal.pone.0024441.g005
Figure 6. Human cd T cells express PLZF. (A) The MFI of PLZF
expression in cd T cells as compared to CD3
+CD56
2CD161
2 T cells (P
value is shown). Histogram shows PLZF expression in cd T cells
collected from two healthy donors in comparison to cd T cells from the
PLZF-deficient donor. (B) The frequency of cd T cells from a healthy
control and the PLZF deficient donor is shown in the panels at the top.
Although the frequency of cd T cell in PLZF deficient sample appears
higher than the controls, the percentage is actually consistent with a
broader analysis (data not shown) and with published reports. The
bottom panels show CD161 and CD8 expression on cd T cells from the
healthy control and the PLZF deficient donor. cd T cells were identified
as shown in the top panels. Data from PLZF deficient donor were
consistent from three independent blood samples. Numbers indicate
the frequency of cells within each panel.
doi:10.1371/journal.pone.0024441.g006
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expressing cell types were altered in some way in samples obtained
from a person with a biallelic loss of functional PLZF. For
example, the phenotype of CD1d-restricted NKT cells was altered
and the frequency of CD161
hiCD8
+ T cells was reduced,
suggesting that these T cells are dependent upon PLZF for
development. cd T cells were present in the PLZF-deficient donor,
but appeared to have altered CD161 and CD8 expression. In the
absence of PLZF, NK cells expressed lower levels of CD56 and the
activating receptors CD16 and CD161. Surprisingly, we found
that PLZF-deficient NK cells produced substantially greater
amounts of several different cytokines. No obvious alterations in
the PLZF-expressing cell types were detected in a limited analysis
of the donor’s mother, who carries a point mutation in one copy
ZBTB16 (data not shown). As mentioned above, the donor’s father
carries two non-mutated copies of the PLZF gene and, therefore,
blood samples were not obtained. Finally, the donor has not shown
overt signs of autoimmunity nor increased susceptibility to
infectious disease. Indeed, although the donor is EBV positive,
he does not display signs of active disease.
Rather surprisingly, we found that PLZF was not expressed in
CD3
+CD56
+ T cells. Nevertheless, the frequency of CD3
+CD56
+
T cells was reduced in the PLZF-deficient donor, implicating
PLZF in the development of these cells. It is possible that
expression of PLZF in CD3
+CD56
+ T cells may occur during T
cell development, when it directs the acquisition of an innate T-
cell phenotype in this population, but is then downregulated prior
to the migration of these cells into the periphery, similar to what
was found for embryonic CD4 T cells [47]. Alternatively, the
reduced frequency of CD56
+ T cells may be due to cell extrinsic
factors, such as altered cytokine expression by other PLZF-
expressing cells.
Recently published data suggests that a large percentage of
CD161
hi CD8
+ and CD161
hi double negative T cells express an
invariant Va7.2 TCRa chain [48]. T cells expressing this invariant
TCR belong to a subset known as mucosal-associated invariant T
cells (MAIT cells). The finding that human, but not mouse, MAIT
cells express PLZF suggests a functional divergence in this T cell
subset.
To begin to understand the role of PLZF-expressing
CD161
hiCD8
+ T cell lineage in the human immune system, we
analyzed the frequency of this population in blood obtained from
patients with either autoimmunity or cancer. Patients with SLE
were found to have a highly significant decrease in the percentage
of CD8
+ T cells within the CD161
hi subpopulation. Similar results
were obtained from a small cohort of patients with primary
Sjo ¨gren’s syndrome. Interestingly, patients with advanced mela-
noma were found to have a significant increase in the frequency of
CD161
hi T cells. In one extreme example, ,16% of the total T
cells were CD161
hi and, in particular, nearly 40% of the patient’s
CD8 T cells were CD161
hi. While these data have not been
correlated with clinical outcomes, it is clear that the PLZF-
expressing population is dynamic and that it changes with different
types of immunological stress.
The patient data are consistent with a previous report showing
that CD161
hi CD8
+ T cells are reduced in patients with a variety
of rheumatic diseases including SLE, MCTD (mixed connective-
tissue disease), SSc (systemic sclerosis) and PM/DM (polymyositis/
dermatomyositis) [45]. Our data are also consistent with a report
showing that CD161
hiCD8
+ T cells do not produce IFN-c, TNF-a
or IL-2 following TCR activation [49]. A more recent paper
suggests that CD161
hiCD8
+ T cells contain an IL-17 producing
subset as well as IL-22 producing cells [50]. Interestingly, it was
found that the IL-17 producing cells were enriched in the livers of
patients during chronic hepatitis. The PLZF-expressing
CD161
hiCD8
+ T cells also express high levels of the IL-18
receptor a chain (data not shown). Therefore it is possible that the
cells we study here are the same or similar to those described as
having the capacity to efflux and, therefore, survive treatments
involving chemotherapy drugs [51]. It was suggested that the
Figure 7. PBMCs from a healthy control and the PLZF-deficient
donor were analyzed by FACS. (A) Histogram shows PLZF levels in
permeabilized CD3
2CD56
+ NK cells. (B) CD56 levels on CD3
2 PBMCs
from a healthy control or the PLZF-deficient donor. CD16 and CD161
levels on CD3
2CD56
+ NK cells (solid line = PLZF-deficient donor;
dotted line = healthy control). (C) CD3
2CD56
+ NK cells were sorted and
then activated with beads coated with anti-NKp46 and anti-CD2.
Supernatants were collected after 72 hours and analyzed by cytokine
bead array. Control-1 was obtained from a healthy donor the day of the
sort; control-2 was obtained from a healthy donor and the sample was
shipped with the PLZF-deficient sample. FACS analysis was consistent
for eight healthy controls. Samples from the PLZF-deficient donor were
collected three times and were analyzed in three independent FACS
experiments. Cells for the cytokine release experiment were collected
from one sample. Sorted cells were split into multiple wells (between 3
and 8 wells) and treated as independent samples for statistical
purposes. (** P value =0.0080; *** P value ,0.0001).
doi:10.1371/journal.pone.0024441.g007
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hi T cells are actually precursors of CD161
lo cells and, thus,
might represent self-renewing stem cell-like memory CD8 T cells
[51]. It will be interesting to determine if these proposed functions
are dependent on PLZF.
Overall, we have found that PLZF is expressed in a greater
variety of lymphocytes and in a higher percentage of lymphocytes
in humans as compared to mice. The function of PLZF-expressing
cells appears to be diverse. For example, CD161
hiCD8
+ T cells
clearly do not make abundant levels of cytokines following
activation. Furthermore, PLZF expression in human NK cells
appears to limit cytokine production. Therefore, in sharp contrast
to other PLZF-expressing lymphocytes, PLZF expression in
human CD8
+ T cells and NK cells appears to inhibit cytokine
expression.
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